Selective estrogen receptor degraders - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Selective Estrogen Receptor Degraders - Pipeline Insight, 2022” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Selective Estrogen Receptor Degraders pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Selective Estrogen Receptor Degraders: Overview
Estrogen receptor (ER) plays important roles in gene transcription and the proliferation of ER positive breast cancers. Selective modulation of ER has been a therapeutic target for this specific type of breast cancer.
Function - Estrogens, a class of steroid hormones, regulate the growth, development, and physiology of the human reproductive system. Estrogens also involve in the neuroendocrine, skeletal, adipogenesis, and cardiovascular systems. Estrogen signaling pathways are selectively stimulated or inhibited depending on a balance between the activities of estrogen receptor (ER) ? or ER? in target organs. ERs belong to the steroid hormone superfamily of nuclear receptors, which act as transcription factors after binding to estrogen. The gene expression regulation by ERs is to modulate biological activities, such as reproductive organ development, bone modeling, cardiovascular system functioning, metabolism, and behavior in both females and males.
Selective Estrogen Receptor Degraders- A selective estrogen receptor degrader or downregulator (SERD) is a type of drug which binds to the estrogen receptor (ER) and, in the process of doing so, causes the ER to be degraded and thus downregulated. They are used to treat estrogen receptor-sensitive or progesterone receptor-sensitive breast cancer, along with older classes of drugs like selective estrogen receptor modulators (SERMs) and aromatase inhibitors.
Selective Estrogen Receptor Degraders Emerging Drugs Chapters
This segment of the Selective Estrogen Receptor Degraders report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Selective Estrogen Receptor Degraders Emerging Drugs
Further product details are provided in the report……..
Selective Estrogen Receptor Degraders: Therapeutic Assessment
This segment of the report provides insights about the different Selective Estrogen Receptor Degraders drugs segregated based on following parameters that define the scope of the report, such as:
Selective Estrogen Receptor Degraders: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Selective Estrogen Receptor Degraders therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Selective Estrogen Receptor Degraders drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Selective Estrogen Receptor Degraders - Pipeline Insight, 2022” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Selective Estrogen Receptor Degraders pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Selective Estrogen Receptor Degraders: Overview
Estrogen receptor (ER) plays important roles in gene transcription and the proliferation of ER positive breast cancers. Selective modulation of ER has been a therapeutic target for this specific type of breast cancer.
Function - Estrogens, a class of steroid hormones, regulate the growth, development, and physiology of the human reproductive system. Estrogens also involve in the neuroendocrine, skeletal, adipogenesis, and cardiovascular systems. Estrogen signaling pathways are selectively stimulated or inhibited depending on a balance between the activities of estrogen receptor (ER) ? or ER? in target organs. ERs belong to the steroid hormone superfamily of nuclear receptors, which act as transcription factors after binding to estrogen. The gene expression regulation by ERs is to modulate biological activities, such as reproductive organ development, bone modeling, cardiovascular system functioning, metabolism, and behavior in both females and males.
Selective Estrogen Receptor Degraders- A selective estrogen receptor degrader or downregulator (SERD) is a type of drug which binds to the estrogen receptor (ER) and, in the process of doing so, causes the ER to be degraded and thus downregulated. They are used to treat estrogen receptor-sensitive or progesterone receptor-sensitive breast cancer, along with older classes of drugs like selective estrogen receptor modulators (SERMs) and aromatase inhibitors.
Selective Estrogen Receptor Degraders Emerging Drugs Chapters
This segment of the Selective Estrogen Receptor Degraders report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Selective Estrogen Receptor Degraders Emerging Drugs
- Elacestrant: Radius Health
- Giredestrant: Genentech
Further product details are provided in the report……..
Selective Estrogen Receptor Degraders: Therapeutic Assessment
This segment of the report provides insights about the different Selective Estrogen Receptor Degraders drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Selective Estrogen Receptor Degraders
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Selective Estrogen Receptor Degraders: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Selective Estrogen Receptor Degraders therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Selective Estrogen Receptor Degraders drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Selective Estrogen Receptor Degraders R&D. The therapies under development are focused on novel approaches for Selective Estrogen Receptor Degraders.
- Selective Estrogen Receptor Degraders Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Selective Estrogen Receptor Degraders drugs?
- How many Selective Estrogen Receptor Degraders drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Selective Estrogen Receptor Degraders?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Selective Estrogen Receptor Degraders therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Selective Estrogen Receptor Degraders and their status?
- What are the key designations that have been granted to the emerging drugs?
- Radius Health
- Genentech
- Olema Pharmaceuticals
- Eli Lilly and Company
- Aragon Pharmaceuticals
- Novartis
- Sanofi
- Sun Pharma Advanced Research Company
- G1 Therapeutics
- Shandong Luoxin Pharmaceutical
- AstraZeneca
- Zeno Alpha
- InventisBio
- Atossa Therapeutics
- Evestra
- Elacestrant
- Giredestrant
- OP 1250
- LY 3484356
- RG 6047
- LSZ 102
- Amcenestrant
- SCO 120
- Rintodestrant
- LX 039
- AZD 9833
- ZN c5
- D 0502
- Fulvestrant intraductal
- EC 372
Introduction
Executive Summary
Selective Estrogen Receptor Degraders: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Selective Estrogen Receptor Degraders – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Selective Estrogen Receptor Degraders companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Selective Estrogen Receptor Degraders Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Elacestrant: Radius Health
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
LY 3484356: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
EC 372: Evestra
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Selective Estrogen Receptor Degraders Key Companies
Selective Estrogen Receptor Degraders Key Products
Selective Estrogen Receptor Degraders- Unmet Needs
Selective Estrogen Receptor Degraders- Market Drivers and Barriers
Selective Estrogen Receptor Degraders- Future Perspectives and Conclusion
Selective Estrogen Receptor Degraders Analyst Views
Selective Estrogen Receptor Degraders Key Companies
Appendix
Executive Summary
Selective Estrogen Receptor Degraders: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Selective Estrogen Receptor Degraders – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Selective Estrogen Receptor Degraders companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Selective Estrogen Receptor Degraders Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Elacestrant: Radius Health
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
LY 3484356: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
EC 372: Evestra
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Selective Estrogen Receptor Degraders Key Companies
Selective Estrogen Receptor Degraders Key Products
Selective Estrogen Receptor Degraders- Unmet Needs
Selective Estrogen Receptor Degraders- Market Drivers and Barriers
Selective Estrogen Receptor Degraders- Future Perspectives and Conclusion
Selective Estrogen Receptor Degraders Analyst Views
Selective Estrogen Receptor Degraders Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Selective Estrogen Receptor Degraders
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Selective Estrogen Receptor Degraders
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Selective Estrogen Receptor Degraders
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Selective Estrogen Receptor Degraders
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
